Use of rituximab in pediatric patients with steroidresistant nephrotic syndrome. A single center study

Introduction: Steroids are the cornerstone of therapy for nephrotic syndrome (NS) with a remission rate as high as 90%. In patients who do not respond to them or are steroid dependent, other immunosuppressive drugs have been used. Although rituximab use in NS is off-label, many authors have publishe...

Full description

Bibliographic Details

Published in:	Iatreia
Main Authors:	Serna-Higuita, Lina María, Vanegas-Ruiz, Juan José, Serrano-Gayubo, Ana Katherina, Vélez-Echeverri, Catalina, Ochoa-García, Carolina Lucía, Rojas-Rosas, Luisa Fernanda, Baquero-Rodríguez, Richard, Nieto-Ríos, John Fredy, Ocampo-Kohn, Catalina, Aristizábal-Alzate, Arbey, Orozco-Forero, Juan Pablo, Flórez, Jesús Antonio, Zuleta-Tobón, John Jairo, Zuluaga-Valencia, Gustavo Adolfo
Format:	Article
Language:	Spanish
Published:	Universidad de Antioquia 2015-01-01
Subjects:	Chronic Renal Disease Immunosuppressive Agents Mycophenolic Acid Nephrotic Syndrome Rituximab
Online Access:	http://aprendeenlinea.udea.edu.co/revistas/index.php/iatreia/article/view/16785